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cell adhesion molecule-1 (VCAM-1), alpha-1 acid glycoprotein
(AGP) and C-reactive Protein (CPR) for two homozygous sickle
cell patients, and it’s association with clinical episodes, hemoglobin
S% determination and donor cell percentages. We report two
patients with Sickle cell disease (SCD) had multiple Cerebro-
Vascular-Accident (CVA) and recurrent vasco-occulsive crises and
failed to respond to chronic transfusion program with Desferal
rescue, underwent HLA-matched Allogenic Bone Marrow Trans-
plantation (BMT). Patients were prepared for transplantation us-
ing standard regimen which comprised Busulfan (BU) 3.5 mg/kg
PO every 6H for total of 16 doses, four days of Cytoxan (50 mg/kg)
and, ATG (30mg/kg) for 3days. Both were given antiseizure pro-
phylaxis from day-2 to day 14 and continued with cyclosporin
(1.5 mg/kg) for 6 months post-transplant and because of poor renal
function patient #1 received methylprednisone 1mg/kg as alterna-
tive to methetotrexate while patient #2 received standard short
course of methetrexate for GVHD prophylaxis. Neutrophil En-
graftment (0.5 109/L) occurred in day10, day14 respectively
with augmentation of GCSF. Both had stable clinical and cytogen-
tic engraftment. Post BMT complication were signiﬁcant for SVS
(superior vena cava syndrome) which completely resolved with r
TPA for patient #1 and chronic cutenous GVHD for patient #2
which managed with steroid. Pre BMT adhesion molecules
VCAM-1, AGP and plasma factor CRP were determined and
correlated with clinical episodes of crises, Hgb S% and donor cell
percentage. VCAM-1 level was 1041 ng/ml, AGP 1.14 mg/L, and
CRP 11.64 mg/L on day –4 for patient #1 which declined by 38%
on day 16 for VCAM-1 16%, and 100% for AGP and CRP
respectively. While VCAM-1 level was 3404 ng/ml, AGP 1.14
mg/L, and CRP 11.64 mg/L for patient #2 on day-2, these were
noticed to decline gradually and reach minimum of 970 ng/ml
(down by 71%) of VCAM-1, 1.0 mg/L of AGP (12%), and almost
100% decrease of CRP. Our results suggest the role of Stem cell
allograft in reversing the progression of vasculopathy through
decreasing adherence and interaction of both red cell, endothelial
cell and plasma factors.
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THE USE OF FLUDARABINE BASED REDUCED INTENSITY CONDITION-
ING FOR THE TREATMENT OF PATIENTS WITH FANCONI’S ANEMIA
Slavin, S., Bitan, M., Aker, M., Resnik, I., Shapira, M.Y., Or, R.
Hadassah-Hebrew University Medical Center, Jerusalem, Israel
Allogeneic stem cell transplantation (SCT) is the only curative
modality for Fanconi’s anemia (FA). FA patients are most susceptible
to alkylating agents and radiation at dose ranges commonly used in
preparation for SCT. For FA, ﬂudarabine based non-myeloablative
stem cell transplantation (NST) is particularly attractive for reducing
toxicity and improving immediate and long-term outcome following
SCT. Sixteen FA patients were transplanted in our center between
1989-2002. Eight patients were transplanted with cyclophosphamide
and ionizing irradiation (total lymphoid irradiation) (CY-TLI). Six
patients were treated, with NST consisting of ﬂudarabine 30mg/
meter sq/day  6; cyclophosphamide 5mg/kg/day 2 and rabbit
anti-T lymphocyte globulin (ATG) 10mg/kg 4. Higher dose of
cyclophosphamide of 10mg/kg/day 2 was used in a patient with
leukemic transformation with thrombocytopenia and 20% myelo-
blasts. The regimen was well tolerated with no transplant related
toxicity or any major complication. However, rejection was observed
when the protocol was applied for a matched unrelated donor
(MUD). A second transplant from another unrelated donor was suc-
cessfully accomplished without complications using a combination of
ﬂudarabine, busulfan 4mg/kg/day 2 and Campath-1H (humanized
anti-CD52), and therefore, it was decided that this protocol will also
be used for a subsequent case. All 8/8 patients treated with NST with
stem cells obtained from a matched sibling or MUD survive, follow-
ing uneventful SCT procedure with 100% donor cell chimerism, fully
reconstituted with no severe acute or chronic GVHD, whereas in the
CY-TLI group 50% are currently alive post transplantation. More-
over, looking at several parameters associated with post-transplant
complications, like fever, infections, the need for total parental nutri-
tion, veno-occlusive disease of the liver and graft-versus-host disease,
NST protocol appears superior according to all parameters. Based on
our data, ﬂudarabine based NST may represent the treatment of
choice for patients with FA with a matched sibling or MUD available.
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REDUCED INTENSITY (RI) CONDITIONING AND ALLOGENEIC HEMATO-
POIETIC STEM CELL TRANSPLANTATION (HSCT) IN PEDIATRIC PA-
TIENTS WITH NON-MALIGNANT DISORDERS
Jacobsohn, D.A., Kletzel, M., Duerst, R. Children’s Memorial Hospital,
Chicago, IL
Because children tolerate intensive regimens with less TRM,
there has been reluctance to use RI regimens in them despite
potential beneﬁt for reduced long-term morbidity. RI regimens are
of interest in children with nonmalignant disorders since there’s no
obvious need for high-dose therapy or GVL. Of 30 pts who
underwent RI HSCT at Children’s Memorial Hospital, 12 (6M,
6F) had nonmalignant disorders. Diagnoses: 5 immunodeﬁciencies
(2 Hyper-IgM, 1 Omenn’s, 1 X-linked lymphoproliferative dis-
ease, 1 chronic granulomatous disease), 3 metabolic disorders (1
Hurler’s, 1 mucolipidosis II/III, 1 Sandhoff), 4 hemoglobinopa-
thies (3 sickle cell, 1 beta-thalassemia). Median age: 6 yrs (range
0.5-22.5). Stem cell sources: PBSC from 6 unrelated donors, 4
matched siblings, 1 mismatched parent, and 1 unrelated cord
blood. Regimen: ﬂudarabine 30 mg/m2 (day (d) –10 to –5), IV
busulfan, 0.8-1 mg/kg8 doses or 3.2 mg/kg 2 doses (d –5 and
–4), and equine ATG 40 mg/kg or rabbit ATG 2 mg/kg (d –4 to
–1). GVHD prophylaxis: CsA (7), CsA/MMF (5). Median time to
ANC 500/ul  19 d (10-61), and to unsupported platelet
count  20,000/ul  16.5 d (10-61). Median time to full donor
chimerism (VNTR 95-100%)  143 d (14-473) in 8 of 11 evalu-
able pts (1 hyper-IgM pt remains a mixed chimera, 2 with hemo-
globinopathies never developed donor chimerism). One hemoglo-
binopathy pt achieved full donor chimerism but rejected at 2 yrs
(after PBSC boost). Post-HSCT PBSC boosts were given to 5 pts
for falling donor chimerism. One pt developed aGVHD II-IV; 3 of
8 surviving past d100 with donor chimerism developed limited (2)
or extensive (1) cGVHD. Median survival is 609 d (7-1251). Of 12
pts, 8 are alive. 100d TRM occurred in 2 (measles encephalitis in
1, ARDS in Omenn’s pt who began conditioning with active
infection/ARDS and died d7). Six of the survivors continue to
show donor chimerism. The 2 survivors with autologous recovery
are hemoglobinopathy pts. Whereas 1 of 4 hemoglobinopathy pts
had sustained engraftment, 7 of the 7 remaining evaluable pts have
stable engraftment. Immunodeﬁciency pts had obvious clinical
beneﬁt from HSCT but more time is needed to assess impact of RI
HSCT in pts with metabolic disorders. In children with nonma-
lignant disorders other than hemoglobinopathies, this RI regimen
is relatively non-toxic and promotes engraftment, even with unre-
lated donors. However, in children with hemoglobinopathies, this
RI regimen is associated with non-engraftment or late graft rejec-
tion and should not be performed.
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A TEST DOSE OF I.V. BUSULFAN (BU) IS PREDICTIVE OF THE AREA
UNDER THE CURVE (AUC) OF A SINGLE DAILY DOSE OF I.V. BU IN
PEDIATRIC PATIENTS UNDERGOING A REDUCED INTENSITY (RI) HE-
MATOPOIETIC STEM CELL TRANSPLANT (HSCT)
Kletzel, M., Jacobsohn, D., Duerst, R. Northwestern University Child-
rens Memorial Hospital, Chicago, IL
High-dose BU-containing chemotherapy has been used in autol-
ogous and allogeneic HSCT. Variations in the PK for oral BU in
pediatric patients have resulted in either decreased effect or in-
creased toxicity. The IV formulation eliminates the variability of
Table.
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absorption . A simple method to assess PK AUC of single dose/
24hrs of IV BU in pediatric patients is described. Patients who
signed informed consent were enrolled. The regimen consisted of
test dose of IV BU (0.8mg/kg) as a single dose day -10, Fludarabine
30mg/m2/day on days –10 to –6, followed by BU 3.2 mg per
Kg/day on days –5 and –4 and rabbit ATG 2mg/kg on days –4 to
–1. Phenytoin prophylaxis was given for 4 days. Cells were infused
on day 0. There were 5 patients with a median age 8.0 (0.5-16
years);. The median weight was 22.6 (range 4.3-45.4) Kg. Patients
diagnoses include: Omenn’s syndrome, Neuroblastoma, ALL,
CML, and X linked lymphoproliferative disease. Samples were
obtained at 2, 4, 8 and 12 hrs and submitted to the Fred Hutchin-
son Cancer Center for determination of the AUC. An AUC of
800-1200 was targeted for the test dose. The median measured
AUC was 1034 (816-1315) uMol*min; the clearance was 3.1 (2.4-
3.9) (ml/min) kg. The target AUC equals the AUC of the test dose
multiplied by 4. The dose of 3.2mg/Kg/q24 hrs was administered
and the target AUC was 3800-4200. The measured AUC median
was 3590 (2307-4097) uMol*min and the clearance 3.4 (3-4.2)(ml/
min)/kg, Dose adjustment of 10% lower dose on days –5, –4 was
made on one patient who had a high AUC, the modiﬁcation resulted
in a lower AUC. No instances of hepatic veno-occlusive disease or
seizures developed. Neutrophil and platelet engraftment was prompt
in 3/3 evaluable patients. Three of the patients have achieved full
chimerism. In conclusion, PK of a test dose of 0.8 mg/Kg of IV BU
multiplied by 4 appears to be predictive of the PK for a single daily
dose of IV BU in pediatric patients undergoing a RI HSCT.
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OUTCOME OF TRANSPLANTATION WITH UNRELATED DONOR BONE
MARROW IN CHILDREN WITH SEVERE THALASSEMIA
Pakakasama, S.1,3, Hongeng, S.1,3, Chaisiripoomkere, W.2,3, Chuan-
sumrit, A.1, Ungkanont, A.2,3, Jootar, S.2,3 1. Department of Pediatrics;
2. Department of Internal Medicine; 3. Bone Marrow Transplant Pro-
gram, Faculty of Medicine, Ramathibodi Hospital, Mahidol University,
Bangkok, Thailand
About 70% of thalassemic patients lack HLA-identical family
members to be suitable donors for bone marrow transplantation
(BMT). To increase therapeutic opportunity for these patients, we
have performed BMT from unrelated donors to children with
severe beta-thalassemia at our institute. The objective of this study
is to determine the outcomes of patients who underwent unrelated
BMT for severe beta-thalassemia. There were 11 patients; 6 ho-
mozygous beta-thalassemia, and 5 severe beta-thalassemia/Hb E
disease. The median age was 3 years (range, 1-11 years). Prepara-
tive regimen consisted of busulfan, cyclophosphamide, and rabbit
anti-thymocyte globulin. The patients received bone marrow from
unrelated donor (6/6 HLA-matched  10, 5/6  1) with a median
CD 34 cell dose of 3.3  106 cells/kg (range, 0.8-6.9  106
cells/kg). GVHD prophylaxis was cyclosporin (CSA) and myco-
phenolate moteﬁl (MMF) (n  7), or tacrolimus (FK 506) and
MMF (n  1), or FK 506 and methotrexate (n  3). The median
day of neutrophil and platelate engraftment was 16 and 26, respec-
tively. Ten patients engrafted with full donor chimerism, one with
mixed chimerism. Six patients (55%) had acute GVHD (gr I  1,
gr II-IV  5). Limited chronic GVHD appeared in 5 patients
(45%). CMV reactivation was detected in 3 patients, no CMV
disease. All patients were alive and well with a median follow-up
time of 16 months (range, 9-30 months). Our data demonstrate
that unrelated BMT could be considered as an optional therapy for
children with severe beta-thalassemia.
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REDUCED INTENSITY CONDITIONING AND ALLOGENEIC STEM CELL
TRANSPLANTATION (RIALLOSCT) FROM UNRELATED CORD BLOOD
AND MATCHED FAMILY DONORS IN CHILDREN AND ADOLESCENT
RECIPIENTS RESULTS IN SUSTAINED DONOR CHIMERISM
Del Toro, G., Satwani, P., Harrison, L., Cheung, Y.-K., Bradley, M.B.,
George, D., Yamashiro, D., Garvin, J., Skerrett, D., Bessmertny, O.,
Wolownik, K., Wischhover, C., van de Ven, C., Cairo, M.S. Children’s
Hospital of New York-Presbyterian, Columbia University, New York, NY
Mixed and ultimately complete donor chimerism have been
achieved in adults following RIAlloSCT from matched related and
unrelated donors (Slavin et al, Blood:99:1071, 2002). However,
there is little data regarding the use of a RIAlloSCT approach in
pediatric recipients. We determined the degree of chimerism by
unique VNTR and STR alleles after RIAlloSCT in children fol-
lowing matched family donor (MFD) stem cell & unrelated um-
bilical cord blood (UCB) transplants. Donors: 14 UCB, 2 BM, 4
PBSC, and 1 BM  PBSC. RIC: Busulfan (Bu)/Fludarabine (Flu)/
r-ATG (N  11); Bu/Flu (N  1); Bu/Flu/Alemtuzumab (N  2);
Flu/Cyclophosphamide (Cy)/r-ATG (N  4); Flu/Melphalan/h-
ATG (N  1); 200 cGy TBI/Flu/Cy/h-ATG (N  1); and Flu/
Cy/etoposide/r-ATG (N  1); GVHD prophylaxis: FK-506 and
MMF. Demographics: median age 13 (0.5-21) yrs; HD (6), NHL
(1), neuroblastoma (2), Wilms’ tumor (1), CML (1), AML (1),
MDS (1), Wiskott-Aldrich syndrome (1), -thal (2), aplastic anemia
(2), Fanconi anemia (1), HLH (1). The UCB median cell dose was
4.3 (0.9-10.8)  107 nc/kg and 1.9 (0.3-6.9)  105 CD34/kg. The
BM/PBSC cell dose was 8.3 (4.7-18.9)  108 nc/kg and 5.0 (4.6-
6.4) 106 CD34/kg. MFD vs. UCB median time to ANC500
2d was 14 (8-22) days vs.18 (2-45) days and platelet count 20,000
untransfused  7d was 11 (8-22) days vs. 21 (6-170) days. Maximal
donor chimerism (MDC) for UCB was 100% for 8 pts, 98% for 1
pt, 95% for 1 pt, 55% for 1 pt (died of PD on day79), and 0% for
3 pts. For related MFD, MDC was 100% for 6 pts, 65% for 1 pt
and 55% for 1 pt. Primary graft failure occurred in 3 patients
(-Thal, MDS, HLH). Secondary graft failure occurred in 2 patients
(AA and -Thal). Grade 4 toxicities were: 1 transaminitis, 1 hyper-
glycemia, and 1 leukoencephalopathy. Opportunistic infectious
complications included: candidemia (N 3), aspergillosis (N 1),
adenovirus (N 4),Mycobacterium spp. (N 2) and one subclinical
CMV infection. The probability of AGVHD grade II-IV in UCB
vs. MFD was 30.1% vs. 46.5%. The overall probability of
CGVHD was 10% at day 200. The probability of 1-yr OS is 69%.
RIAlloSCT in children and adolescents appears feasible and toler-
able and results in 70% achieving 90% sustained mixed donor
chimerism within 2 months. The risk of graft failure following
RIAlloSCT in children and adolescents is similar to adults (Maris
et al, Blood 102:2021, 2003) and occurs mainly in non-malignant
diseases (-Thal, MDS, AA, HLH).
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NONMYELOABLATIVE TRANSPLANT IN CHILDHOOD DISEASES
Chik, K.W., Li, C.K., Shing, M.M.K., Lee, V., Yuen, P.M.P. Depart-
ment of Paediatrics, The Chinese University of Hong Kong, Hong Kong
SAR, China
Nonmyeloablative transplant provides a cure for seriously ill
children with lesser degree of toxicity. We report our experience
on ﬂudarabine based preparatory regimen in 12 subjects (M:F 
5:7, median age 95 months) from September 1999 to June 2002.
There were acute lymphoblastic leukemia(1), acute myeloid leuke-
mia(1), chronic myeloid leukemia(1), severe aplastic anemia(5),
Fanconi anemia(1), Wiskott Aldrich syndrome(1), Omenn syn-
drome(1) and I cell disease(1). They were either with complications
from prior intensive chemotherapy, second transplant, mismatched
related donors/cord blood or matched unrelated donors. The con-
ditioning regimen consists of ﬂudarabine 30mg/m2 for 5 days from
day-8, cyclophosphamide 60mg/kg for 2 days from day-3 and
anti-thymocyte globulin 30mg/kg (10mg/kg for HLA-identical
related transplant) for 3 days from day-3. The donor graft was not
T cell depleted with median CD34 count of 4.12  106/kg. The
neutrophil engraftment occurred at median of 16 days (9-29),
platelet transfusion independence at median of 21 days and red
blood cell transfusion independence at median of 23 days. No
conﬁrmed septicemia was noted. One patient had herpes simplex
encephalitis on day 32 with signiﬁcant physical handicap. No other
major toxicity was noted. Three developed mixed chimerism with
subsequent conversion to complete chimerism by either with-
drawal of immunosuppressives or donor leucocyte infusion. The
patient with I cell disease had stable mixed chimerism and re-
mained clinically stable. Two had mixed chimerism and then re-
jection of the donor graft. The remaining 6 remained in complete
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